GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Subscribe To Our Newsletter & Stay Updated